The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
 
Joshua Bauml
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Foundation Medicine; Genentech; Guardant Health; Inivata; Janssen; Merck; Novartis; Novartis; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Byoung Chul Cho
Leadership - Gencurix; Interpark Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus Therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus Therapeutics; Guardant Health; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Oscotec; Pfizer; Roche; Takeda; Yuhan
Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
Other Relationship - DAAN Biotherapeutics
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; JNJ; Lilly; LOXO; Merck KGaA; MSD; Ono Pharmaceutical; Puma Biotechnology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
 
EUN KYUNG CHO
No Relationships to Disclose
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
Sang-We Kim
No Relationships to Disclose
 
Eric B. Haura
Consulting or Advisory Role - Amgen; Ellipses Pharma; Janssen Oncology; Janssen Research & Development; Revolution Medicines
Research Funding - AstraZeneca (Inst); Genentech (Inst); Incyte; Janssen (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Protein-Protein Interactions as Biomarkers Patent
 
Joshua K. Sabari
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Medscape; Navire; Pfizer; Regeneron; Takeda
 
Rachel E. Sanborn
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Lilly; EMD Serono; Genentech/Roche; Janssen Oncology; Macrogenics
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck
Travel, Accommodations, Expenses - AstraZeneca
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Novartis; Takeda
Speakers' Bureau - Blueprint Medicines
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Elevation Oncology; Turning Point Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Genentech/Roche; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - AstraZeneca; Genentech/Roche
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Anna Rachel Minchom
Honoraria - Bayer; Chugai Pharma; Faron Pharmaceuticals; Merck; Novartis Pharmaceuticals UK Ltd.
Consulting or Advisory Role - Janssen Oncology
Research Funding - Seagen
Travel, Accommodations, Expenses - Amgen
 
Jorge E. Gomez
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - AstraZeneca; Atara Biotherapeutics
Speakers' Bureau - BMS
Research Funding - JNJ (Inst)
Travel, Accommodations, Expenses - Atara Biotherapeutics; Bristol-Myers Squibb; Celgene
 
Joshua C. Curtin
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Grace Gao
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Amy Roshak
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Meena Thayu
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Roland Elmar Knoblauch
Employment - Johnson & Johnson; Johnson & Johnson (I)
Stock and Other Ownership Interests - Johnson & Johnson; Johnson & Johnson (I)
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Gritstone Bio; incyte; Jazz Pharmaceuticals; Merck (Inst); Mirati Therapeutics; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Takeda (Inst); Trovagene (Inst)